RAS Interaction with PI3K: More Than Just Another Effector Pathway
Open accessThe DOI matches its Crossref record; 205 of the 206 references it cites were found in a registry or an index.
Abstract
RAS PROTEINS ARE SMALL GTPASES KNOWN FOR THEIR INVOLVEMENT IN ONCOGENESIS: around 25% of human tumors present mutations in a member of this family. RAS operates in a complex signaling network with multiple activators and effectors, which allows them to regulate many cellular functions such as cell proliferation, differentiation, apoptosis, and senescence. Phosphatidylinositol 3-kinase (PI3K) is one of the main effector pathways of RAS, regulating cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism. However, it is the involvement of this pathway in human tumors that has attracted most attention. PI3K has proven to be necessary for RAS-induced transformation in vitro, and more importantly, mice with mutations in the PI3K catalytic subunit p110α that block its ability to interact with RAS are highly resistant to endogenous oncogenic KRAS-induced lung tumorigenesis and HRAS-induced skin carcinogenesis. These animals also have a delayed development of the lymphatic vasculature. Many PI3K inhibitors have been developed that are now in clinical trials. However, it is a complex pathway with many feedback loops, and interactions with other pathways make the results of its inhibition hard to predict. Combined therapy with another RAS-regulated pathway such as RAF/MEK/ERK may be the most effective way to treat cancer, at least in animal models mimicking the human disease. In this review, we will summarize current knowledge about how RAS regulates one of its best-known effectors, PI3K.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Network analysis of the several driver mutation genes, including KMT2D138, PIK3CA139, PTEN140, and IDH1141, that regulate signaling and metabolic pathways in KRAS-driven cancers, connects them to oncogenic RAS (Fig 4c).”
From The metabolic landscape of RAS-driven cancers from biology to therapy (2021) · cites this paper as [138]
The cited source says what the claim attributes to it.
In the citing paper
“Oncogenic KRAS signaling also involves PI3K-AKT-mTOR, via the interaction with the catalytic subunits of PI3K (78–80).”
From New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness (2019) · cites this paper as [78]
The cited source says what the claim attributes to it.
In the citing paper
“An additional layer of complexity is the cross-regulation between the two pathways with ERK signaling feeding into several nodes of PI3K/mTOR such as its phosphorylation of TSC236–38.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, W., Zhu, T., & Guan, K.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405730200 · Cited by 78
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery
Datta, S. R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., & Greenberg, M. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80405-5 · Cited by 5,689
The phosphoinositide 3-kinase pathway
Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Research works printed but not linked: 1
- [5]5. Wolfman A, Macara IG. A cytosolic protein catalyzes the release of GDP from p21ras. Science. 1990;248:67-9 [DOI] [PubMed] [Google Scholar]
Cited by
Items 101–200 of 764
Iglesias, D. A., Yates, M. S., van der Hoeven, D., Rodkey, T. L., Zhang, Q., Co, N. N., Burzawa, J. K., Chigurupati, S., Celestino, J., Bowser, J. L., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0439 · Cited by 88
RAS and downstream RAF-MEK and PI3K-AKT signaling in neuronal development, function and dysfunction
Zhong, J. (2016) · Biological Chemistry · doi:10.1515/hsz-2015-0270 · Cited by 88
“The major downstream signaling pathways triggered by RAS activation, namely the RAFMEK-ERK and PI-3 kinase-AKT-mTOR cascades, have been extensively reviewed elsewhere (Reichardt, 2006; Castellano and Downward, 2011).”
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Tang, D., Kroemer, G., & Kang, R. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01422-7 · Cited by 80
Single-Molecule Study Reveals How Receptor and Ras Synergistically Activate PI3Kα and PIP3 Signaling
Buckles, T. C., Ziemba, B. P., Masson, G. R., Williams, R. L., & Falke, J. J. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.09.018 · Cited by 78
“In the enzyme activation model, G-protein increases the specific activity (or turnover number) of each membrane-bound, G-protein-associated, kinase molecule (14,17).”
BackgroundThe Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
Nussinov, R., Muratcioglu, S., Tsai, C.-J., Jang, H., Gursoy, A., & Keskin, O. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0165 · Cited by 78
“The low binding af fi nity of p110/K-Ras4B and the catalytic enhancement (8-to 10-fold) of p110 by GTP-bound K-Ras (19) highlight the importance of membrane localization of p110 a via p85 nSH2 domain binding to the phosphorylated tyrosine of RTKs (or GPCR or cytokine receptors for p110 g ) or their associated adaptor p…”
BackgroundA bright future for KRAS inhibitors
Bar-Sagi, D., Knelson, E. H., & Sequist, L. V. (2020) · Nature Cancer · doi:10.1038/s43018-019-0016-8 · Cited by 74
Guenther, M. K., Graab, U., & Fulda, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.010 · Cited by 80
The higher level of complexity of K‐Ras4B activation at the membrane
Jang, H., Banerjee, A., Chavan, T. S., Lu, S., Zhang, J., Gaponenko, V., & Nussinov, R. (2016) · The FASEB Journal · doi:10.1096/fj.15-279091 · Cited by 76
Takashina, M., Inoue, S., Tomihara, K., Tomita, K., Hattori, K., Zhao, Q., Suzuki, T., Noguchi, M., Ohashi, W., & Hattori, Y. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3859 · Cited by 76
“Akt is a direct downstream effector of PI3K (36,37), and PI3K can be activated by the protein superfamily of small GTPase Ras (38).”
Jang, H.-J., Lee, A., Kang, J., Song, I. H., & Lee, S. H. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i40.6207 · Cited by 75
Fibroblast growth factor signaling in mammalian tooth development
Li, C., Procházka, J., Goodwin, A. F., & Klein, O. D. (2013) · Odontology · doi:10.1007/s10266-013-0142-1 · Cited by 81
“cell survival [46].”
Jun, J. E., Rubio, I., & Roose, J. P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00239 · Cited by 93
PI3K: A Crucial Piece in the RAS Signaling Puzzle
Krygowska, A. A., & Castellano, E. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031450 · Cited by 84
“The involvement of oncogenic RAS and PI3K in migration and remodeling of actin cytoskeleton has been well established through their interaction with Rac and Rho proteins both in mammalian cells and in the slime mold Dictyostelium discoideum (Campbell and Der 2004; Giehl 2005; Pollock et al. 2005; Sasaki and Firtel 200…”
BackgroundSelf-citationActivation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
Chen, J., Zhao, K., Li, R., Shao, R., & Chen, C. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140414095605 · Cited by 77
“Ras can interact with catalytic subunit of PI3K – p110 and activate PI3K activity independent of PI3K regulatory subunit p85 [43].”
BackgroundThe RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions
Nakhaeizadeh, H., Amin, E., Nakhaei-Rad, S., Dvorsky, R., & Ahmadian, M. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0167145 · Cited by 71
Ausoni, S., Boscolo‐Rizzo, P., Singh, B., Mosto, M. C. D., Spinato, G., Tirelli, G., Spinato, R., & Azzarello, G. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9625-1 · Cited by 73
“The oncogene product RAS is also a positive regulator of the PI3K signaling cascade, resulting in cell survival and cell cycle regulation [67].”
BackgroundWang, J., Pollard, K., Allen, A. N., Tomar, T., Pijnenburg, D., Yao, Z., Rodriguez, F. J., & Pratilas, C. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1365 · Cited by 69
Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma
Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.021 · Cited by 75
“in BRAF mutant melanoma (see Sections 6 and 7) (Castellano and Downward, 2011).”
BackgroundBlock one, unleash a hundred. Mechanisms of DAB2IP inactivation in cancer
Bellazzo, A., Minin, G. D., & Collavin, L. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.134 · Cited by 74
Kapùs, A., & Janmey, P. A. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120015 · Cited by 83
The structural basis for Ras activation of PI3Kα lipid kinase
Zhang, M., Jang, H., & Nussinov, R. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp00101h · Cited by 74
Understanding genomics and the immune environment of penile cancer to improve therapy
Aydın, A. M., Chahoud, J., Adashek, J. J., Azizi, M., Magliocco, A. M., Ross, J. S., Necchi, A., & Spiess, P. E. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0359-z · Cited by 70
Singh, M., Suman, S., & Shukla, Y. (2014) · BioMed Research International · doi:10.1155/2014/243452 · Cited by 83
An overview on the biological activity and anti-cancer mechanism of lovastatin
Xie, L., Zhu, G., Shang, J., Chen, X., Zhang, C., Ji, X., Zhang, Q., & Wei, Y. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110122 · Cited by 74
Muthuswami, M., Ramesh, V., Banerjee, S., Thangaraj, S. V., Periasamy, J., Rao, D. B., Barnabas, G. D., Raghavan, S., & Ganesan, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077553 · Cited by 70
“The effector signals downstream of RAS could be ERK/MAPK signalling or PI3K/AKT signalling which are involved in cell survival and proliferation [49].”
BackgroundProtein Tyrosine Phosphatases: Mechanisms in Cancer
Sivaganesh, V., Sivaganesh, V., Scanlon, C., Iskander, A., Maher, S., Le, T. H., & Peethambaran, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312865 · Cited by 72
Nakai, Y., Isayama, H., Sasaki, T., Mizuno, S., Sasahira, N., Kogure, H., Kawakubo, K., Yamamoto, N., Hirano, K., Ijichi, H., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825de678 · Cited by 63
Ras signaling in aging and metabolic regulation
Slack, C. (2017) · Nutrition and Healthy Aging · doi:10.3233/nha-160021 · Cited by 67
“Extensive cross-talk occurs between Ras/MAPK signaling and PI3K/AKT signaling via both stimulatory and inhibitory mechanisms (Fig.”
BackgroundInfluentialSeshacharyulu, P., Rachagani, S., Muniyan, S., Siddiqui, J. A., Cruz, E., Sharma, S., Krishnan, R., Killips, B. J., Sheinin, Y. M., Lele, S. M., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0791-9 · Cited by 67
Imai-Sumida, M., Chiyomaru, T., Majid, S., Saini, S., Nip, H., Dahiya, R., Tanaka, Y., & Yamamura, S. (2017) · Oncotarget · doi:10.18632/oncotarget.20734 · Cited by 66
Dufresne, S., Rébillard, A., Muti, P. C., Friedenreich, C. M., & Brenner, D. R. (2018) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-16-0969 · Cited by 69
Dai, H., Song, D., Xu, J., Li, B., Hertz, L., & Peng, L. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.09.005 · Cited by 66
“Although PI3K is one of the major downstream signals of RAS (Castellano and Downward, 2011), there is also evidence that PI3K activates MAPK/ERK1/2 pathway at or upstream of RAS (Hawes et al.”
BackgroundThyroid C-Cell Biology and Oncogenic Transformation
Cote, G. J., Grubbs, E. G., & Hofmann, M.-C. C. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-22542-5_1 · Cited by 70
Tripathi, K., & Garg, M. (2018) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-017-0441-3 · Cited by 66
Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0545 · Cited by 61
“Interestingly, STAT1 expression has been reported to be repressed by signaling mediated by oncogenic RAS, which is upstream of PI3K signaling (32, 33).”
BackgroundThe quaternary assembly of KRas4B with Raf-1 at the membrane
Jang, H., Zhang, M., & Nussinov, R. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.03.018 · Cited by 57
Overcoming Resistance to Drugs Targeting KRAS Mutation
Jiao, D., & Yang, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100035 · Cited by 61
Starvation, detoxification, and multidrug resistance in cancer therapy
Lee, C., Raffaghello, L., & Longo, V. D. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.004 · Cited by 62
Implications of KRAS mutations in acquired resistance to treatment in NSCLC
Re, M. D., Rofi, E., Restante, G., Crucitta, S., Arrigoni, E., Fogli, S., Maïo, M. D., Petrini, I., & Danesi, R. (2017) · Oncotarget · doi:10.18632/oncotarget.23553 · Cited by 68
“G12D-induced benign lung tumors in genetically engineered mouse models [59].”
BackgroundCombination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment
Kim, M. J., Lee, S. J., Ryu, J. H., Kim, S. H., Kwon, I. C., & Roberts, T. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.019 · Cited by 67
CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma
Trietsch, M. D., Spaans, V. M., ter Haar, N. T., Osse, E. M., Peters, A. A. W., Gaarenstroom, K. N., & Fleuren, G. J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.07.094 · Cited by 61
“It seems that a dual blockade of upstream RAS by MEK inhibitors, and a more downstream inhibition of PI3K, may have better clinical results than single pathway blocking treatment [28].”
BackgroundTIMP-2 Interaction with MT1-MMP Activates the AKT Pathway and Protects Tumor Cells from Apoptosis
Valacca, C., Tassone, E., & Mignatti, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0136797 · Cited by 59
“Because AKT can also be activated by Ras [52,53], we hypothesized that TIMP-2 activation of Ras results in the downstream activation of both ERK1/2 and AKT.”
BackgroundInfluentialModeling the Transitions between Collective and Solitary Migration Phenotypes in Cancer Metastasis
Huang, B., Jolly, M. K., Lu, M., Tsarfaty, I., Ben‐Jacob, E., & Onuchic, J. N. (2015) · Scientific Reports · doi:10.1038/srep17379 · Cited by 58
Naidu, S., Shi, L., Magee, P., Middleton, J. D., Laganà, A., Sahoo, S., Leong, H. S., Galvin, M., Frese, K. K., Dive, C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14843-6 · Cited by 60
The Ins and Outs of RAS Effector Complexes
Kiel, C., Matallanas, D., & Kölch, W. (2021) · Biomolecules · doi:10.3390/biom11020236 · Cited by 63
“, phosphoinositide-3 kinase (PI3K) [28].”
InfluentialMultiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure
Ouwerkerk, W., Pereira, J. P. B., Maasland, T., Emmens, J. E., Figarska, S. M., Tromp, J., Koekemoer, A. L., Nelson, C. P., Nath, M., Romaine, S. P. R., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.053 · Cited by 66
Tamaskovic, R., Schwill, M., Nagy‐Davidescu, G., Jöst, C., Schaefer, D. C., Verdurmen, W. P. R., Schaefer, J. V., Honegger, A., & Plückthun, A. (2016) · Nature Communications · doi:10.1038/ncomms11672 · Cited by 62
Vascular Stains: Proposal for a Clinical Classification to Improve Diagnosis and Management
Rozas‐Muñoz, E., Frieden, I. J., Roé, E., Puig, L., & Baselga, E. (2016) · Pediatric Dermatology · doi:10.1111/pde.12939 · Cited by 58
SOX9-PDK1 axis is essential for glioma stem cell self-renewal and temozolomide resistance
Wang, Z., Xu, X., Liu, N., Cheng, Y., Jin, W., Zhang, P., Wang, X., Yang, H., Liu, H., & Tu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.22773 · Cited by 60
“PIP3 brings PDK1 and AKT to the membrane, where PDK1 activates AKT by phosphorylation at residue threonine 308 [32, 33].”
BackgroundCancer vaccines: Targeting KRAS-driven cancers
Zhang, Y., Ma, J., Zhang, H.-X., Jiang, Y., & Luo, W. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1733420 · Cited by 63
“RAS proteins are small GTPases located on the inner leaflet of the plasma membrane that bind to guanosine triphosphate (GTP) or guanosine diphosphate (GDP) [7,8].”
BackgroundBhat, S., Kabekkodu, S. P., Adiga, D., Fernandes, R. C., Shukla, V., Bhandari, P., Pandey, D., Sharan, K., & Satyamoorthy, K. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09582-4 · Cited by 57
Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)
Mustafa, M., Abbas, K., Alam, M., Ahmad, W., Moinuddin, M., Usmani, N., Siddiqui, S. A., & Habib, S. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04772-6 · Cited by 67
“The SOS protein can also trigger the activation of the minor GTPase Ras, which leads to the activation of the downstream PI3K/Akt kinase cascade [59].”
Molecular subtypes in canine hemangiosarcoma reveal similarities with human angiosarcoma
Wang, G., Wu, M., Durham, A. C., Radaelli, E., Mason, N. J., Xu, X., & Roth, D. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229728 · Cited by 55
Differential signaling during macropinocytosis in response to M-CSF and PMA in macrophages
Yoshida, S., Gaeta, I., Pacitto, R., Krienke, L., Alge, O., Gregorka, B., & Swanson, J. A. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00008 · Cited by 56
“Alternatively, Ras may be part of a positive feedback loop controlling macropinosome formation by regulating PI3K (Castellano and Downward, 2011).”
BackgroundRole of miRNALet-7and Its Major Targets in Prostate Cancer
Wagner, S., Ngezahayo, A., Escobar, H. M., & Nolte, I. J. A. (2014) · BioMed Research International · doi:10.1155/2014/376326 · Cited by 67
“PI3Ks belong to one of the main effector molecules of RAS [151].”
BackgroundMundt, F., Rajput, S., Li, S., Ruggles, K. V., Mooradian, A. D., Mertins, P., Gillette, M. A., Krug, K., Guo, Z., Hoog, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1990 · Cited by 58
“However, connections to MAPK/MEK and PLK1 signaling were also observed, and MAPK/MEK signaling is well known to confer resistance to PI3K inhibition (reviewed in Castellano and Downward [42]).”
BackgroundBery, N., Cruz-Migoni, A., Bataille, C. J., Quevedo, C. E., Tulmin, H., Miller, A., Russell, A., Phillips, S. E., Carr, S. B., & Rabbitts, T. H. (2018) · eLife · doi:10.7554/elife.37122 · Cited by 55
“We have also explored the second best-characterized RAS effector family, the RAS-PI3Ka-AKT pathway (Castellano and Downward, 2011) by establishing a KRAS/full-length PI3Ka (herein PI3Ka) biosensor.”
BackgroundPI3 kinase inhibitors in the clinic: an update.
Kurtz, J., & Ray-Coquard, I. L. (2012) · PubMed · Cited by 64
Zañudo, J. G. T., Scaltriti, M., & Albert, R. (2017) · Cancer Convergence · doi:10.1186/s41236-017-0007-6 · Cited by 64
“These latter rules are consistent with signaling in certain types of lung cancer (23,24).”
BackgroundWang, Y., Zhang, Z., Wang, H., Zhang, Y., Ji, M., Xu, H., Wang, C., Sun, Z., Gao, W., & Wang, S. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1551-4 · Cited by 54
“Subsequent studies have demonstrated that PDK1 was highly expressed in a majority of human cancer cell lines and metastasized breast tumors (Castellano and Downward 2011; Fyffe and Falasca 2013).”
BackgroundAsati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 61
Erban, T., Sopko, B., Kadlikova, K., Talacko, P., & Harant, K. (2019) · Scientific Reports · doi:10.1038/s41598-019-45764-1 · Cited by 53
Ummanni, R., Mannsperger, H., Sonntag, J., Oswald, M., Sharma, A. K., König, R., & Korf, U. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2013.11.017 · Cited by 53
“Multiple signaling pathways are known to be involved in the initiation and progression of lung cancer [32–34].”
BackgroundRAS signalling in energy metabolism and rare human diseases
Dard, L., Bellancé, N., Lacombe, D., & Rossignol, R. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.05.003 · Cited by 62
ST6Gal1: Oncogenic signaling pathways and targets
Sajina, G. C., Bellis, S. L., & Hjelmeland, A. B. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.962908 · Cited by 60
“This pathway is activated in a multitude of cancers and, in turn, leads to uncontrolled cell growth, migration, invasion and therapeutic resistance (Castellano and Downward, 2011; Jiang et al., 2020).”
BackgroundShymanets, A., Prajwal, P., Bucher, K., Beer‐Hammer, S., Harteneck, C., & Nürnberg, B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.508234 · Cited by 62
Dort, M. E. V., Hong, H., Wang, H., Nino, C. A., Lombardi, R. L., Blanks, A., Galbán, S., & Ross, B. D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01655 · Cited by 52
“36 mmol) in DMF (6 mL) was added in portions to a solution of 3,4-difluoro-2-(2-fluoro-4iodophenylamino)benzoic acid pentafluorophenyl ester21 (3) (3.”
MethodSu, C.-C., Wang, C., Huang, K.-H., Lee, Y., Chan, W.-M., & Chang, Y. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.07.032 · Cited by 61
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 53
“These interactions regulate apoptosis (Cantley, 2002; Castellano & Down- ward, 2011; Chang et al., 2003; Duronio, 2008).”
BackgroundDoes Ras Activate Raf and PI3K Allosterically?
Nussinov, R., Tsai, C.-J., & Jang, H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01231 · Cited by 50
“Conformational changes, elicited primarily by the nSH2 domain of p85α, are a key step in PI3Kα activation (51, 52).”
BackgroundKRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma
Norton, C., Shaw, M. S., Rubnitz, Z., Smith, J. L., Soares, H. P., Nevala-Plagemann, C., Garrido‐Laguna, I., & Florou, V. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.53588 · Cited by 57
Chen, C.-C., Liu, T.-Y., Huang, S.-P., Ho, C., & Huang, T. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.07.014 · Cited by 49
Tyrosine Phosphorylation of CD13 Regulates Inflammatory Cell–Cell Adhesion and Monocyte Trafficking
Subramani, J., Ghosh, M., Rahman, M., Caromile, L. A., Gerber, C., Rezaul, K., Han, D. K. M., & Shapiro, L. H. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301348 · Cited by 51
“has been implicated in a number of PI3K-dependent functions (26).”
BackgroundSudhan, D. R., Guerrero-Zotano, A., Won, H., González Ericsson, P., Servetto, A., Huerta-Rosario, M., Ye, D., Lee, K.-M., Formisano, L., Guo, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.013 · Cited by 49
“RAS are small GTPases that undergo oncogenic activation in ~25% cancers through mechanisms including mutations in its GTP binding domain, downregulation of RAS inactivating GAP proteins, and/or RTK overexpression (Castellano and Downward, 2011).”
BackgroundSignaling Circuits on the G olgi Complex
Cancino, J., & Luini, A. (2012) · Traffic · doi:10.1111/tra.12022 · Cited by 51
Dort, M. E. V., Galbán, S., Wang, H., Sebolt, J. S., Whitehead, C. E., Hong, H., Rehemtulla, A., & Ross, B. D. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.02.053 · Cited by 52
“Studies have shown that there is a link (feedback loop) between the PI3K and MEK pathways giving rise to redundancy in survival pathways [9-14].”
BackgroundReduced risk of apoptosis: mechanisms of stress responses
Milisav, I., Poljšak, B., & Ribarič, S. (2016) · APOPTOSIS · doi:10.1007/s10495-016-1317-3 · Cited by 52
“PI3K is essential for RAS-elicited cell transformation in vitro [121].”
BackgroundPI3K inhibition in breast cancer: Identifying and overcoming different flavors of resistance
Vitale, S. R., Martorana, F., Stella, S., Motta, G., Inzerilli, N., Massimino, M., Tirrò, E., Manzella, L., & Vigneri, P. G. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103334 · Cited by 53
Spatial organization of PI3K-PI(3,4,5)P3-AKT signaling by focal adhesions
Wang, J., An, Z., Wu, Z., Zhou, W., Sun, P., Wu, P., Dang, S., Xue, R., Bai, X., Du, Y., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.10.010 · Cited by 51
Nikolakopoulou, Z., Nteliopoulos, G., Michael-Titus, A. T., & Parkinson, E. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt257 · Cited by 49
“This is not surprising as EGFR has been reported to enhance ERK phosphorylation downstream of MEK through dual-specificity phosphatases (48) but could result in a signalling imbalance that has previously been shown to trigger apoptosis (41,42) or senescence (43).”
BackgroundRas Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 54
“For these difficulties, attention has shifted to targeting downstream effectors of Ras, mostly the Raf-MAPK [33-35] and PI3K-Akt [36, 37] cascades, in tumors with hyperactive Ras.”
BackgroundInfluentialAspirin sensitivity of PIK3CA-mutated Colorectal Cancer: potential mechanisms revisited
Hall, D. C. N., & Benndorf, R. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04430-y · Cited by 54
Saranya, J., Shilpa, G., Raghu, K. G., & Priya, S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00034 · Cited by 49
“Also by interacting with p110 subunit of PI3K, activated Ras mediated oncogenic transformation (Castellano and Downward, 2011).”
BackgroundMEK inhibitors in oncology: a patent review (2015-Present)
Mahapatra, D. K., Asati, V., & Bharti, S. K. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1339688 · Cited by 47
“Ras protein is responsible for post-regulation of different kinases such as Raf, MEK, ERK, JNK, PI3K, Akt, NFκB, and others those further regulate various cell functions [11,14,15].”
BackgroundThakuri, P. S., Gupta, M., Singh, S. K., Joshi, R., Glasgow, E. F., Lekan, A. A., Agarwal, S., Luker, G. D., & Tavana, H. (2020) · BMC Cancer · doi:10.1186/s12885-019-6479-2 · Cited by 50
Cirstea, I. C., Gremer, L., Dvorsky, R., Zhang, S.-C., Piekorz, R. P., Zenker, M., & Ahmadian, M. R. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds426 · Cited by 45
“Briefly, PI3K activation by RAS leads to the production of phosphatidylinositol 3,4,5-trisphosphate, activation of phosphoinositide-dependent kinase-1 that leads in turn to AKT-activating phosphorylation at threonine 308 (22).”
BackgroundNussinov, R., Zhang, M., Tsai, C., Liao, T.-J., Fushman, D., & Jang, H. (2018) · Biophysical Reviews · doi:10.1007/s12551-018-0461-0 · Cited by 50
“…(PIP3) from phosphatidylinositol 4,5-bisphosphate (PIP2), a critical signaling molecule that stimulates the PI3K/Akt/mTOR (mammalian target of rapamycin) pathway, which regulates cell growth and survival, cytoskeleton reorganization, and metabolism (Castellano and Downward 2011).”
BackgroundRas Pathways on Prox1 and Lymphangiogenesis: Insights for Therapeutics
Bui, K., & Hong, Y. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.597374 · Cited by 48
“Phosphatidylinositol 3-kinase (PI3K) can be activated by one of three means: the direct binding of PI3K’s regulatory subunit p85α by (1) Ras, (2) the scaffolding protein known as growth factor receptorbound protein 2 (Grb2)-associated binder (GAB), or (3) the receptor tyrosine kinase itself (125).”
BackgroundCrosstalk between nitric oxide and hypoxia-inducible factor signaling pathways: an update
Poyton, R., & Hendrickson, M. (2015) · Research and Reports in Biochemistry · doi:10.2147/rrbc.s58280 · Cited by 45
“Finally, NO can both directly and indirectly inhibit 26S proteasome activity, though indirect is likely the predominant mechanism, as direct inhibition only occurs at physiologically irrelevant NO concentrations.(76) Although it has been reported that protein tyrosine nitration increases transiently upon cell exposure…”
Optogenetic control of signaling in mammalian cells
Beyer, H. M., Naumann, S., Weber, W., & Radziwill, G. (2014) · Biotechnology Journal · doi:10.1002/biot.201400077 · Cited by 48
“Apart from RAF, the PI3K is a well-characterized RAS effector protein [69].”
BackgroundPhosphatidylinositol‐3,4,5‐trisphosphate: Tool of choice for class I PI 3‐kinases
Salamon, R. S., & Backer, J. (2013) · BioEssays · doi:10.1002/bies.201200176 · Cited by 55
“All the p110 catalytic subunits contain a Ras-binding domain, although direct binding to Ras-GTP has only been demonstrated for p110a, p110d, and p110g [30].”
BackgroundWang, L.-L., Hao, S., Zhang, S., Guo, L., Hu, C., Zhang, G., Gao, B., Zhao, J., Jiang, Y., Tian, W., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.07.040 · Cited by 45
“On one hand, PI3K, a phosphatidylinositol kinase including a regulatory subunit, p85, and a catalytic subunit, p110, promotes cell growth, cell cycle entry, cell survival, cytoskeleton reorganization, and metabolism; and it is the involvement of PI3K in human tumors that has attracted the most attention [23,24].”
BackgroundBlood Vascular Abnormalities in Rasa1 Knockin Mice
Lubeck, B. A., Lapinski, P. E., Bauler, T. J., Oliver, J. A., Hughes, E. D., Saunders, T. L., & King, P. D. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.08.018 · Cited by 46
Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma
Shen, J., Tsoi, H., Liang, Q., Chu, E. S. H., Liu, D., Yu, A. C.-S., Chan, T. F., Li, X., Sung, J. J. Y., Wong, V. W. S., et al. (2016) · Oncogene · doi:10.1038/onc.2016.162 · Cited by 44
KIF1Bβ mutations detected in hereditary neuropathy impair IGF1R transport and axon growth
Xu, F., Takahashi, H., Tanaka, Y., Ichinose, S., Niwa, S., Wicklund, M., & Hirokawa, N. (2018) · The Journal of Cell Biology · doi:10.1083/jcb.201801085 · Cited by 48
“4 and S4), and overexpression of Ras V12 that directly stimulates MAPK and PI3K signaling pathways (Kuemmerle and Murthy, 2001; Castellano and Downward, 2011) could rescue the axonal outgrowth phenotype (Fig.”
BackgroundResultZhang, Z., & Richmond, A. J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.648663 · Cited by 48
“The PI3K pathway engages in crosstalk with the RAS-RAF-MEK-ERK pathway at multiple nodes of interaction (Castellano and Downward, 2011).”
BackgroundTubular lysosomes harbor active ion gradients and poise macrophages for phagocytosis
Suresh, B., Saminathan, A., Chakraborty, K., Zajac, M. A., Cui, C., Becker, L., & Krishnan, Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113174118 · Cited by 45
“Third, PI3K activity leads to mTOR activation tubulating lysosomes (3, 60).”
BackgroundGutierrez, E., Cahatol, I., Bailey, C., Lafargue, A. M., Zhang, N., Song, Y., Tian, H., Zhang, Y., Chan, R., Gu, K., et al. (2019) · Cancers · doi:10.3390/cancers11060818 · Cited by 46
Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment
McDaniel, C. G., Adams, D. M., Steele, K. E., Hammill, A. M., Merrow, A. C., Crane, J. L., Smith, C. L., Kozakewich, H. P., & Cras, T. D. L. (2023) · Pediatric Blood & Cancer · doi:10.1002/pbc.30219 · Cited by 44
Nakhaei‐Rad, S., Haghighi, F., Nouri, P., Adariani, S. R., Lissy, J., Jasemi, N. S. K., Dvorský, R., & Ahmadian, M. R. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1431605 · Cited by 45
“PI3K-AKT pathway is very well known in controlling cell cycle entry, cell growth, survival, and metabolism (Castellano and Downward 2011).”
Background
Metadata
- Authors
- Castellano, E., & Downward, J.
- Affiliations
- Cancer Research UK (GB)
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 261-274
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- PMC
- PMC3128635
- OpenAlex
- W2047401805
- Cited by
- 762
- References
- 206
- Citations by year
- 2026: 32 · 2025: 38 · 2024: 50 · 2023: 52 · 2022: 48 · 2021: 82 · 2020: 69 · 2019: 59 · 2018: 50 · 2017: 43 · 2016: 55 · 2015: 54 · 2014: 42 · 2013: 45 · 2012: 37
- FWCI
- 17.03
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- Ras, phosphatidylinositol 3-kinase, oncogenic KRAS, HRAS, p110α, PI3K inhibitors, Raf/MEK/ERK pathway, combination cancer therapy, tumor resistance, lung carcinogenesis, skin carcinogenesis, small GTPases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.